141190-94-5

Basic information

• Product Name: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER
• Synonyms: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER;(S)-N-BOC-PHENYLALANINE METHYL ESTER;Methyl 2-((tert-butoxycarbonyl)aMino)-2-phenylacetate
• CAS NO: 141190-94-5
• Molecular Formula: C₁₄H₁₉NO₄
• Molecular Weight: 265.3
• Mol File: 141190-94-5.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER(141190-94-5)
• EPA Substance Registry System: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER(141190-94-5)

Safety Data

• Hazardous Substances Data: 141190-94-5(Hazardous Substances Data)

Usage

Property

Different sources of media describe the Property of 141190-94-5 differently. You can refer to the following data:
1. Name
Content: ALFA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENACETIC ACID METHYL ESTER
2. Common Name
Content: ACEMETHACIN
3. Type
Content: Non-steroidal anti-inflammatory drug (NSAID)
4. Uses
Content: Used to relieve pain and reduce inflammation in conditions such as arthritis
5. Mechanism of Action
Content: Works by inhibiting the production of prostaglandins
6. Conditions Treated
Content: Osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders
7. Form
Content: Oral tablet
8. Prescription
Content: Typically prescribed by a healthcare professional
9. Caution
Content: Should be used with caution and under the guidance of a medical professional to minimize the risk of side effects and complications.

Upstream product

• 33125-05-2 Boc-D-Phg-OH 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 204126-99-8 methyl (2R)-N-benzyl-2-(acetoxyamino)-2-phenylethanoate 
• 19883-41-1 D-phenylglycine methyl ester hydrochloride 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 
• 24461-61-8 (R)-Phenylglycine methyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 4248-19-5 tert-butyl carbazate 
• 100-52-7 benzaldehyde 
• 150884-50-7 benzaldehyde N-boc imine 
• 155396-71-7 tert-butyl N-(phenyl(phenylsulfonyl)methyl)carbamate 
• 685132-79-0 tert-butyl [(1R)-2-nitro-1-phenylethyl]carbamate 

Downstream Products

• 223906-34-1 (2R)-N-Boc-2-amino-1,1,2-triphenylpropanol 
• 310450-36-3 (1R,R_S)-N-(tert-butoxycarbonyl)-1-amino-1-phenyl-3-(p-tolylsulfinyl)-2-propanone 
• 1173806-01-3 (R)-methyl 2-(tert-butoxycarbonyl(methyl)amino)-2-phenylacetate 
• 875768-53-9 (S)-5,5-diethyl-4-phenyloxazolidin-2-one 
• 1456505-11-5 (S)-4-(5,5-diethyl-2-oxo-4-phenyloxazolidin-3-yl)-N-(quinolin-8-yl)benzamide 
• 875768-49-3 (R)-tert-butyl (2-ethyl-2-hydroxy-1-phenylbutyl)carbamate 
• 223906-33-0 ((R)-2-hydroxy-2-methyl-1-phenyl-propyl)-carbamic acid tert-butyl ester 
• 1610360-90-1 (R)-2,2-dimethyl-1-((2-nitrophenyl)sulfonyl)-3-phenylaziridine 
• 1610360-96-7 (R)-N-(2-hydroxy-2-methyl-1-phenylpropyl)-2-nitrobenzenesulfonamide 
• 1617545-81-9 (R)-1-[6-(5-chloro-2-fluoro-phenyl)-pyrazin-2-ylamino]-2-methyl-1-phenyl-propan-2-ol 
• 1587732-49-7 C₁₉H₁₇N₃O₂ 
• 1587732-57-7 C₁₉H₁₇N₃O₂ 
• 1268694-24-1 N-Boc-(R)-4-phenyloxyphenylglycine methyl ester 
• 1126635-26-4 tert-butyl N-[(R)-phenyl(hydrazinecarbonyl)methyl]carbamate 

Relevant articles and documents

Enantioselective syntheses of α-, β-, and γ-aryl amino acids and esters

-

Nitrogen-Doped Carbon Enables Heterogeneous Asymmetric Insertion of Carbenoids into Amines Catalyzed by Rhodium Nanoparticles

Development of stable heterogeneous catalyst systems is a crucial subject to achieve sustainable society. Though metal nanoparticles are robust species, the study of asymmetric catalysis by them has been restricted because methods to activate metal nanopa

Structure-based design of inhibitors of the aspartic protease endothiapepsin by exploiting dynamic combinatorial chemistry

Structure-based design (SBD) can be used for the design and/or optimization of new inhibitors for a biological target. Whereas de novo SBD is rarely used, most reports on SBD are dealing with the optimization of an initial hit. Dynamic combinatorial chemistry (DCC) has emerged as a powerful strategy to identify bioactive ligands given that it enables the target to direct the synthesis of its strongest binder. We have designed a library of potential inhibitors (acylhydrazones) generated from five aldehydes and five hydrazides and used DCC to identify the best binder(s). After addition of the aspartic protease endothiapepsin, we characterized the protein-bound library member(s) by saturation-transfer difference NMR spectroscopy. Cocrystallization experiments validated the predicted binding mode of the two most potent inhibitors, thus demonstrating that the combination of de novo SBD and DCC constitutes an efficient starting point for hit identification and optimization. The dynamic duo: The combination of de novo structure-based design and dynamic combinatorial chemistry has been applied to the identification of novel acylhydrazone-based inhibitors for the aspartic protease endothiapepsin. 1H-STD-NMR spectroscopy has been used to identify the binders from the dynamic combinatorial libraries. Proposed binding modes of the most potent inhibitors have been confirmed by X-ray crystallography.

OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.